MR Spectroscopy of Pediatric Brain Disorders

Magnetic resonance spectroscopy (MRS) is a modality available on most clinical MR scanners and readily integrated with standard MR imaging (MRI). For the brain in particular, MRS has been a powerful research tool providing additional clinically relevant information for several disease families such as brain tumors, metabolic disorders, and systemic diseases. The most widely-available MRS method, proton (1H; hydrogen) spectroscopy, is FDA approved for general use in the US and can be ordered by clinicians for patient studies if indicated.

There are several books available that describe applications of MRS in adults. However, to the best of our knowledge there is currently no book available that focuses exclusively on applications in pediatrics. MR spectroscopy in the pediatric population is different from adults for two main reasons. Particularly in the newborn phase the brain undergoes biochemical maturation with dramatic changes of the "normal" biochemical fingerprint. Secondly, brain diseases in the pediatric population are different from adult disorders. For example, brain tumors, which are mostly gliomas in the adults, often originate from different cell types and are also more diverse even within the same type and grade of tumor. This diversity of diseases and its implications for MR spectroscopy has not been addressed sufficiently in the literature, we believe. The target audience for "MR Spectroscopy of Pediatric Brain Disorders" are thus both clinicians and researchers involved with pediatric brain disorders. This includes radiologists, neurologists, neurooncologists, neurosurgeons, and more broadly the neuroscience and neurobiology community.

This book will provide the necessary background information to understand the basics of MR spectroscopy. This will be followed by a detailed discussion of the normal biochemical maturation which will highlight the metabolic differences between the pediatric and adult brain. Thereafter, in SECTION I